RESUMO
Objective To investigate the expression and action mechanism of miR-98 in colon cancer tissues. Methods Tumor tissues and adjacent tissues were collected from 40 patients with colorectal cancer. The expression of miR-98 in tumor tissues and adjacent tissues was detected by real-time PCR. miR-98 was overexpressed or silenced in cells,and the effects on proliferation,cell cycle,and apoptosis were analyzed using MTT,flow cytometry,and Hoechst 33258 assays. Results Real-time PCR showed that the expression of miR-98 in tumor tissues was lower than that in adjacent tissues (P = 0.022). The survival rate of patients with lower miR-98 expression was shorter than that of patients with higher miR-98 expression. The MTT assay showed that miR-98 overexpression inhibited the proliferation of HCT116 cells. Hoechst 33258 staining showed that the overexpression of miR-98 could inhibit the cell cycle and promote the apoptosis of HCT116 cells. Conclusion miR-98 can inhibit the proliferation and promote the apoptosis of colon cancer cells. The expression of miR-98 is closely related to the survival of patients with colon cancer.
RESUMO
Objective To investigate the relationship among the plasma levels of fibrinogen and the lung cancer,and its clinical significance.Methods From 2011 to 2013,121 cases newly diagnosed lung cancer patients(lung cancer group) and 37 cases healthy individuals(control group) were evaluated.The patients had no history of coagulation system disorders or anticoagulant therapy.Plasma prothrombin time (PT), activated partial thromboplastin time(APTT), thrombin time (TT), fibrin original (FIB), platelet (PLT) of the patients were obtained.The relationship between the plasma levels of fibrinogen and clinical characteristics, therapy modalities (surgery, chemotherapy and radiotherapy), therapy outcomes and survival durations of the patients were analyzed.Results (1) Serum levels of fibrinogen at stage Ⅱ A, stage Ⅱ B, stage Ⅲ A, stage Ⅲ B, stage Ⅳ were (2.001±0.813) g/L, (2.191±0.827) g/L, (3.121 ±2.016) g/L, (4.174±0.595) g/L, (4.332 ± 1.534) g/L, a significant difference was observed between the fibrinogen levels of patients with stage Ⅱ A and those with stage Ⅳ disease (P＜0.001), and there were no significant differences among other stages (P＞0.05).(2)The mean fibrinogen level was significantly higher in the patient group with ECOG performance status 2 than in the other groups(r=0.613,P＜0.05).The mean fibrinogen level was (3.780±1.731) g/L (95％CI,3.122-4.439,P＜0.001) in the group with ECOG 0, (4.182 ± 1.661) g/L(95％CI 3.583-4.781 ,P＜0.001) in the group with ECOG 1 ,and (4.725±2.153) g/L(95％CI,4.007-5.443,P＜0.001) in the group with ECOG 2.(3) The treatment responses of 81 patients who received chemotherapy and/or radiotherapy without surgical intervention were evaluated, serum levels of fibrinogen in 39 patients with partial remission (PR) were (4.005 ±1.177) g,/L,42 patients with stable disease(SD) were (3.192±0.479) g/L, 17 patients with progressive disease(PD) were (7.530± 1.885) g/L,fibrinogen levels were found to be significantly higher in cases with progression,and the difference was significant(P =0.015).(4)Correlation analysis on fibrinogen and chnical indicator: clinical stage (r =0.529, P =0.008), ECOG score (r =0.273, P =0.031), therapy response (r =0.529, P=0.012) were positively correlated with fibrinogen levels.(5)Fibrinogen levels in patients with lung cancer were higher than those of the control group ((2.891 ± 0.484) g/L vs.(3.586± 1.692) g/L, t =-4.620, P ＜0.05), and the difference was statistically significant (P＜0.01).(6)The survival duration was significantly longer in patients with lower fibrinogen levels(321 d vs.435 d,P＜0.05).The mean fibrinogen concentration in patients who were still alive at the end of a 2-year follow-up was (3.531 ± 1.482) g/L, whereas the meanfibrinogen level of patients who died was (3.725± 2.063) g/L, and the difference between the two groups was significant(P =0.015).Conclusion The results suggest that Fibrinogen plasma levels might be useful to predict the clinical outcome and survival of patients with lung cancer.
RESUMO
OBJECTIVE: The Krukenberg tumor is a metastatic or primary malignant ovarian tumor of the signet-ring cell type. The incidence of this tumor is higher in Korea than in western, among relatively young age group with poor prognosis. We evaluated the clinical characteristics of the Krukenberg tumor (metastasized from stomach cancer) and the relationship between the survival and clinical characteristics (including treatment modalities). METHODS: We analyzed 32 cases of the Krukenberg tumor metastasized from stomach cancer at the Department of Obstetrics and Gynecology, Kosin University Gospel Hospital. RESULTS: Among the 32 cases of the Krukenberg tumor, the age distribution ranged from 22 to 58 years, and the mean age was 38.8 years. The most common chief complaint was lower abdominal pain(11 cases). The majority of the stomach cancer showed serosal invasion and was signet-ring cell type in histology. The mean survival was 20 months. In patients with ascites(22 cases), the mean survival was 16 months in contrast to 25 months in ascites-free patients(10 cases). In the chemotherpy group, the mean survival was 23 months in contrast to 16 months in chemotherpy-free group. Also, longer mean survival(25months) was shown in cases with optimal surgery group than non-optimal surgery group. CONCLUSIONS: The survival of krukenberg tumor was shown to be related to the surigcal resectability and chemotherpy modalities.